Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany; Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Australia.
Acad Pediatr. 2018 Jan-Feb;18(1):8-19. doi: 10.1016/j.acap.2017.06.006. Epub 2017 Jun 10.
Herbal medicines are particularly regarded as an alternative or complement to conventional pharmaceuticals in the treatment and prevention of respiratory tract infections (RTIs). Therefore, the purpose of this review was to identify evidence for herbal therapy in the treatment of RTIs concerning effectiveness and safety.
Medline/PubMed, Scopus, and the Cochrane Library were searched through February 12, 2015. Randomized controlled trials that compared herbal therapy with no treatment, placebo, or any pharmaceutical medication in children and adolescents (age 0 to 18 years) with RTI were eligible.
Eleven trials with 2181 participants were included. No clear evidence for Echinacea (4 trials) or an herbal compound preparation (1 trial) in preventing RTI symptoms was found. Meta-analysis revealed evidence for efficacy (responder rates: risk ratio [RR], 2.56; 95% confidence interval [CI], 1.54-4.26; P < .01; heterogeneity: I = 38%; chi-square = 9.63; P = .14) and safety (patients with adverse events: RR, 1.06; 95% CI, 0.42-2.66; P = .9; heterogeneity: I = 72%; chi-square = 10.64; P = .01) of Pelargonium sidoides in treating RTI symptoms compared with placebo (6 trials).
Because of conflicting evidence in the included studies no concrete conclusion on effects of Echinacea could be drawn so far. In the case of Pelargonium sidoides, meta-analysis revealed moderate evidence for efficacy and safety in the treatment of RTIs in children.
草药在治疗和预防呼吸道感染 (RTI) 方面尤其被视为传统药物的替代或补充。因此，本综述的目的是确定草药疗法治疗 RTI 的疗效和安全性证据。
检索了 Medline/PubMed、Scopus 和 Cochrane 图书馆，检索时间截至 2015 年 2 月 12 日。符合条件的研究为比较草药疗法与无治疗、安慰剂或任何药物治疗儿童和青少年 (0 至 18 岁) RTI 的随机对照试验。
纳入了 11 项试验，共 2181 名参与者。没有明确的证据表明紫锥菊 (4 项试验) 或草药复合制剂 (1 项试验) 能预防 RTI 症状。荟萃分析显示，疗效有证据支持 (应答率：风险比 [RR]，2.56；95%置信区间 [CI]，1.54-4.26；P < 0.01；异质性：I = 38%；chi-square = 9.63；P = 0.14) 和安全性 (发生不良事件的患者：RR，1.06；95% CI，0.42-2.66；P = 0.9；异质性：I = 72%；chi-square = 10.64；P = 0.01) ，与安慰剂相比，Pelargonium sidoides 治疗 RTI 症状 (6 项试验)。
由于纳入研究的证据相互矛盾，目前尚不能得出关于紫锥菊作用的确切结论。在 Pelargonium sidoides 的情况下，荟萃分析显示，在儿童 RTI 治疗方面，疗效和安全性有中等证据支持。
